JENNIFER LEE: Open Payments
NPI 1871927574 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,382 in 32 payments from 11 companies in 2025. Trend: 2023 $250 · 2024 $977 · 2025 $1,382
Food & beverage: $1,382
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $290 |
| ABBVIE INC. | 10 | $220 |
| Supernus Pharmaceuticals, Inc. | 5 | $177 |
| E.R. Squibb & Sons, L.L.C. | 3 | $167 |
| Neurocrine BioSciences, Inc. | 2 | $150 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Lundbeck LLC | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
Products named: REXULTI, VRAYLAR, Qelbree, COBENFY, INGREZZA, Auvelity, CAPLYTA, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
